Functional improvement of dystrophic muscle by myostatin blockade
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Mice and cattle with mutations in the myostatin (GDF8) gene show a marked increase in body weight and muscle mass, indicating that this new member of the TGF-beta superfamily is a negative regulator of skeletal muscle growth. Inhibition of the myostatin gene product is predicted to increase muscle mass and improve the disease phenotype in a variety of primary and secondary myopathies. We tested the ability of inhibition of myostatin in vivo to ameliorate the dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD). Blockade of endogenous myostatin by using intraperitoneal injections of blocking antibodies for three months resulted in an increase in body weight, muscle mass, muscle size and absolute muscle strength in mdx mouse muscle along with a significant decrease in muscle degeneration and concentrations of serum creatine kinase. The functional improvement of dystrophic muscle by myostatin blockade provides a novel, pharmacological strategy for treatment of diseases associated with muscle wasting such as DMD, and circumvents the major problems associated with conventional gene therapy in these disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The interest in myostatin was generated by recent studies where antibodies for myostatin were created and administered to adult rodents, which resulted in an increase in body mass, muscle mass, muscle size, and strength [11,12].”
From Effects of methoxyisoflavone, ecdysterone, and sulfo-polysaccharide supplementation on training adaptations in resistance-trained males (2006) · cites this paper as [12]
Citations
Cites
Textbook of Medical Physiology
(1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-6-1363_2 · Cited by 9,749
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
TEXTBOOK OF MEDICAL PHYSIOLOGY
GUYTON, A. C. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196701000-00031 · Cited by 2,837
Dystrophin expression in the mdx mouse restored by stem cell transplantation
Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., Flint, A. F., Kunkel, L. M., & Mulligan, R. C. (1999) · Nature · doi:10.1038/43919 · Cited by 1,802 · cited 1×
“In comparison with conventional transgenic, cell and gene therapy approache”
BackgroundX chromosome-linked muscular dystrophy (mdx) in the mouse
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1189 · Cited by 1,765
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 1×
“Alterations in Smad 2 and 3 phosphorylation would be predicted to regulate the formation of Smad complexes, their nuclear translocation and transcriptional regulation of genes associated with commitment of muscle progenitor”
BackgroundA deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526 · cited 1×
“The regimen did not completely reverse dystrophic changes; physiological parameters evaluated by ex vivo tests, such as susceptibility to damage by lengthening contraction”
BackgroundAhima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Self-citation
Research works printed but not linked: 2
- Jalenak, M. et al. Transcriptional changes arising from in vivo inhibition of myostatin. J. Neurol. Sci. 199 (suppl)., S83 (2002)
- Engel, A. G. & Franzini-Armstrong, C. Myology (McGraw-Hill, New York, 1994)
Cited by
Items 101–200 of 853
Are Human and Mouse Satellite Cells Really the Same?
Boldrin, L., Muntoni, F., & Morgan, J. E. (2010) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2010.956201 · Cited by 144
Sako, D., Grinberg, A. V., Liu, J., Davies, M. V., Castonguay, R., Maniatis, S., Andreucci, A. J., Pobre, E. G., Tomkinson, K. N., Monnell, T. E., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.114959 · Cited by 152
A Wnt-TGFβ2 axis induces a fibrogenic program in muscle stem cells from dystrophic mice
Biressi, S., Miyabara, E. H., Gopinath, S. D., M. Carlig, P. M., & Rando, T. A. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008411 · Cited by 143
“Several members of the TGFb superfamily have been previously implicated in DMD pathogenesis (31, 35, 36, 76, 77), but the specific role exerted by each member in determining the enhanced TGFb signaling observed in dystrophic muscle remains uncertain.”
BackgroundYang, W., Chen, Y., Zhang, Y., Wang, X., Yang, N., & Zhu, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3060 · Cited by 144
“Similarly, the blockade of endogenous myostatin in mdx mice (a Duchenne muscular dystrophy model) resulted in increases of muscle mass, size, and strength along with a significant decrease in muscle degeneration (3, 4).”
BackgroundWasting mechanisms in muscular dystrophy
Shin, J. S., Tajrishi, M. M., Ogura, Y., & Kumar, A. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.001 · Cited by 161
Regulation of muscle atrophy in aging and disease
Vinciguerra, M., Musaro, A., & Rosenthal, N. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-7002-2_15 · Cited by 149
Signaling pathways weigh in on decisions to make or break skeletal muscle
Guttridge, D. C. (2004) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/01.mco.0000134364.61406.26 · Cited by 149
Sun, C., Li, S., Yang, C.-L., Xue, R., Xi, Y., Wang, L., Zhao, Q.-L., & Li, D. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.655019 · Cited by 154
“Currently, three distinct routes were developed for treatment of muscular dystrophy: 1) cellular treatments based on stem cell delivery (30); 2) genetic/molecular treatments based on exon skipping after RNA delivery (31), overexpression of insulin-like growth factor or AKT (32, 33), and activation of compensatory proc…”
BackgroundRetractedBiglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice
Amenta, A. R., Yilmaz, A., Bogdanovich, S., McKechnie, B. A., Abedi, M., Khurana, T. S., & Fallon, J. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013067108 · Cited by 159
“We injected mdx mice at 3-wk intervals (starting at P14) with either rhBGN or vehicle until 15 wk of age, and measured muscle physiology as previously described (21, 22).”
MethodSelf-citationSouza, T. A., Chen, X., Guo, Y., Sava, P., Zhang, J., Hill, J. J., Yaworsky, P. J., & Qiu, Y. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0290 · Cited by 142
“Moreover, blockade of myostatin resulted in functional improvement of dystrophic muscle in the mdx mouse model of Duchenne Muscular Dystrophy (DMD) (8, 9).”
BackgroundInfluentialLatres, E., Pangilinan, J., Miloscio, L., Bauerlein, R., Na, E., Potocky, T. B., Huang, Y., Eckersdorff, M., Rafique, A., Mastaitis, J., et al. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0060-8 · Cited by 143
“It has previously been reported that administration of myostatin-directed monoclonal antibodies in adult mice increases muscle mass and strength and attenuates muscle atrophy [20–25].”
Effects of Heavy Resistance Training on Myostatin mRNA and Protein Expression
WILLOUGHBY, D. S. (2004) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000121952.71533.ea · Cited by 138
Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone
Turgeman, T., Hagai, Y., Huebner, K. D., Jassal, D. S., Anderson, J. E., Genin, O., Nagler, A., Halevy, O., & Pines, M. (2008) · Neuromuscular Disorders · doi:10.1016/j.nmd.2008.06.386 · Cited by 142
Chien, K. R., & Karsenty, G. (2005) · Cell · doi:10.1016/j.cell.2005.02.006 · Cited by 150
“, 2002), while antibodies which block myostatin can augment muscle growth in dystrophic muscle (Bogdanovich et al., 2002).”
Bier, A., Berenstein, P., Kronfeld, N., Morgoulis, D., Ziv-Av, A., Goldstein, H., Kazimirsky, G., Cazacu, S., Meir, R., Popovtzer, R., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.055 · Cited by 145
The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity
Akpan, I., Goncalves, M. D., Dhir, R., Yin, X., Pistilli, E. E., Bogdanovich, S., Khurana, T. S., Ucran, J., Lachey, J., & Ahima, R. S. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.162 · Cited by 140
“Twitch and tetanic responses were evaluated as previously described (5, 23, 24).”
InfluentialSelf-citationAnimal Models for Genetic Neuromuscular Diseases
Vainzof, M., Ayub-Guerrieri, D., Onofre-Oliveira, P. C. G., Martins, P. C. M., Lopes, V. F., Zilberztajn, D., Maia, L. S., Sell, K., & Yamamoto, L. U. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-9023-9 · Cited by 154
“Because of the important role of myostatin in muscle development and regeneration, therapies blocking myostatin have been tested for muscular dystrophies in animal models (Bogdanovich et al. 2002).”
BackgroundMyostatin from the heart: local and systemic actions in cardiac failure and muscle wasting
Breitbart, A., Auger-Messier, M., Molkentin, J. D., & Heineke, J. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00200.2011 · Cited by 131
“For example, inhibition of myostatin by antibody (clone JA-16 or PF-354) has been shown to ameliorate muscle pathology and to increase strength, especially in younger mice with different forms of muscular dystrophy (16, 59, 61, 86).”
BackgroundCadena, S. M., Tomkinson, K. N., Monnell, T. E., Spaits, M. S., Kumar, R., Underwood, K. W., Pearsall, R. S., & Lachey, J. L. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00866.2009 · Cited by 134
“Consistent with results reported from previous myostatin blockade experiments (8, 47), ACE-031 administration produced a significant increase in body weight that corroborated an increase in muscle mass.”
Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass
Sakuma, K., & Yamaguchi, A. (2012) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1007/s13539-011-0052-4 · Cited by 137
“2F (Sgcg), and amyotrophic lateral sclerosis (SOD1 transgenic mouse) [125–127].”
BackgroundBergen, H. R., Farr, J. N., Vanderboom, P. M., Atkinson, E. J., White, T. A., Singh, R. J., Khosla, S., & LeBrasseur, N. K. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0047-5 · Cited by 137
“Such interventions have been shown to increase skeletal muscle mass and improve parameters of strength and physical function in preclinical models of aging and disease [12, 37, 38].”
Therapeutics for Duchenne muscular dystrophy: current approaches and future directions
Bogdanovich, S., Perkins, K. J., Krag, T. O. B., & Khurana, T. S. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0484-1 · Cited by 154
“Recent studies from our laboratory have shown that blockage of endogenous myostatin using anti-myostatin antibodies results in anatomical, biochemical, and physiological improvement in the dystrophic phenotype in mdx mice [159].”
BackgroundSelf-citationDe Paepe, B., & De Bleecker, J. L. (2013) · Mediators of Inflammation · doi:10.1155/2013/540370 · Cited by 129
“Inhibition of myostatin with a neutralizing antibody [79], soluble decoy receptor [80], or myostatin binding propeptide [81] has also been put forward.”
BackgroundPatel, K., & Amthor, H. (2005) · Neuromuscular Disorders · doi:10.1016/j.nmd.2004.10.018 · Cited by 134
Cisplatin-Induced Skeletal Muscle Dysfunction: Mechanisms and Counteracting Therapeutic Strategies
Conte, E., Bresciani, E., Rizzi, L., Cappellari, O., Luca, A. D., Torsello, A., & Liantonio, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041242 · Cited by 143
Extrinsic regulation of satellite cell specification
Bentzinger, C., von Maltzahn, J., & Rudnicki, M. A. (2010) · Stem Cell Research & Therapy · doi:10.1186/scrt27 · Cited by 129
“Indeed, it has been demonstrated that myostatin defi ciency or systemic application of inhibitory antibodies slows down the degeneration in dystrophic muscle of mdx mice [53].”
BackgroundMolecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies
Chakkalakal, J. V., Thompson, J., Parks, R. J., & Jasmin, B. J. (2005) · The FASEB Journal · doi:10.1096/fj.04-1956rev · Cited by 148
“The mechanism whereby MSTN improves muscle function is not known but appears not to involve an increase in the expression of the dystrophin homologue called utrophin (107).”
BackgroundInfluentialModeling human muscle disease in zebrafish
Guyon, J. R., Steffen, L. S., Howell, M. H., Pusack, T. J., Lawrence, C., & Kunkel, L. M. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.07.003 · Cited by 149
“Down-regulation of myostatin in the mdx mouse can help mitigate the symptoms of muscular dystrophy [91, 92] suggesting that decreased expression of myostatin might be a viable therapy to treat people with muscle disease, especially those in which muscle degeneration is a secondary effect.”
BackgroundMurphy, K. T., Koopman, R., Naim, T., Léger, B., Trieu, J., Ibebunjo, C., & Lynch, G. S. (2010) · The FASEB Journal · doi:10.1096/fj.10-159608 · Cited by 124
Heregulin ameliorates the dystrophic phenotype in mdx mice
Krag, T. O. B., Bogdanovich, S., Jensen, C. J., Fischer, M. D., Hansen-Schwartz, J. A., Javazon, E. H., Flake, A. W., Edvinsson, L. I., & Khurana, T. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405972101 · Cited by 140
Self-citationMyostatin: more than just a regulator of muscle mass
Argilés, J. M., Orpí, M., Busquets, S., & López-Soriano, F. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.02.001 · Cited by 125
Zhu, J., Li, Y., Lu, A., Gharaibeh, B., Ma, J., Kobayashi, T., Quintero, A., & Huard, J. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.008 · Cited by 136
Shavlakadze, T., White, J. D., Hoh, J. F. Y., Rosenthal, N. A., & Grounds, M. D. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.026 · Cited by 135
“For example, reduced dystropathology in mdx mice is seen where the growth factor myostatin is absent [4] or blocked by specific antibodies [5] and by overexpression of membrane-associated proteins such as utrophin [6], integrin-a7 [7], and ADAM-12 [8].”
BackgroundLiu, Y., Yan, X., Sun, Z., Chen, B., Han, Q., Li, J., & Zhao, R. C. (2007) · Stem Cells and Development · doi:10.1089/scd.2006.0118 · Cited by 121
“Because increased serum CK levels were consistently noted in mdx mice with dystrophin deficiency (34,35), we assessed serum CK levels in mice in which Flk-1 (cid:2) AD-MSCs were injected.”
Muscular atrophy of caveolin-3–deficient mice is rescued by myostatin inhibition
Ohsawa, Y., Hagiwara, H., Nakatani, M., Yasue, A., Moriyama, K., Murakami, T., Tsuchida, K., Noji, S., & Sunada, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28520 · Cited by 120
“Intraperitoneal administration of a mAb against myostatin or the myostatin prodomain improves the phenotype of mdx mice (37, 38); however, the precise molecular mechanism by which myostatin inhibition improves the phenotype of dystrophin-deficient skeletal muscle is not fully understood, and, to our knowledge, an inte…”
Porter, J. D., Merriam, A. P., Leahy, P. S., Gong, B., Feuerman, J. M., Cheng, G., & Khanna, S. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddh033 · Cited by 123
“Inhibition of the negative regulator of myogenesis, Gdf8 (myostatin), functionally improves dystrophic muscle (63), including reduction of fibrosis and fat accumulation in diaphragm (64).”
BackgroundAn overview of the endocrinology of skeletal muscle
Sheffield‐Moore, M., & Urban, R. J. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.02.009 · Cited by 134
“82 Bogdanovich, S. et al. (2002) Functional improvement of dystrophic”
BackgroundWelle, S., Burgess, K., & Mehta, S. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90862.2008 · Cited by 117
Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?
Miura, P., & Jasmin, B. J. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.01.002 · Cited by 137
Toxicity of a First-Generation Adenoviral Vector in Rhesus Macaques
Lozier, J. N., Csákó, G., Mondoro, T. H., Krizek, D. M., Metzger, M. E., Costello, R., Vostal, J. G., Rick, M. E., Donahue, R. E., & Morgan, R. A. (2002) · Human Gene Therapy · doi:10.1089/10430340152712665 · Cited by 128
Concise Review: Epigenetic Regulation of Myogenesis in Health and Disease
Sincennes, M., Brun, C. E., & Rudnicki, M. A. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0266 · Cited by 132
Thompson, W. R., Scott, A., Loghmani, M. T., Ward, S. R., & Warden, S. J. (2015) · Physical Therapy · doi:10.2522/ptj.20150224 · Cited by 122
“65,68 Combining pharmacological inhibition of myostatin with mechanotherapies may lead to greater improvements in functional recovery, with initial work revealing myostatin inhibition to enhance the effects of exercise on performance in aged mice.”
BackgroundEmergent Dilated Cardiomyopathy Caused by Targeted Repair of Dystrophic Skeletal Muscle
Townsend, D., Yasuda, S., Li, S., Chamberlain, J. S., & Metzger, J. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.52 · Cited by 118
Yoshimura, M., Sakamoto, M., Ikemoto, M., Mochizuki, Y., Yuasa, K., Miyagoe-Suzuki, Y., & Takeda, S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.025 · Cited by 116
Pistilli, E. E., Bogdanovich, S., Goncalves, M. D., Ahima, R. S., Lachey, J. L., Seehra, J. S., & Khurana, T. S. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.071 · Cited by 120
“It was indeed surprising that we observed no improvements in diaphragm or limb muscle histopathology or hydroxyproline content in the present study with sActRIIB therapy, given that both antibody-mediated and propeptide-mediated MSTN inhibition did improve histopathology in mdx diaphragm muscle.(21,22) A possible expl…”
BackgroundMethodResultInfluentialSelf-citationStructural basis for potency differences between GDF8 and GDF11
Walker, R. G., Czepnik, M., Goebel, E. J., McCoy, J. C., Vujic, A., Cho, M., Oh, J., Aykul, S., Walton, K. L., Schang, G., et al. (2017) · BMC Biology · doi:10.1186/s12915-017-0350-1 · Cited by 111
Consalvi, S., Saccone, V., Giordani, L., Minetti, G., Mozzetta, C., & Puri, P. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00049 · Cited by 124
Molecular Mechanisms and Treatment Options for Muscle Wasting Diseases
Rüegg, M. A., & Glass, D. J. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100537 · Cited by 109
Genetic Analysis of the Role of Proteolysis in the Activation of Latent Myostatin
Lee, S.-J. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001628 · Cited by 113
“In this respect, several engineered and endogenous myostatin binding proteins have been demonstrated to be capable of increasing muscle growth when administered to normal and/or dystrophic mice [10–14].”
BackgroundMuscle growth after postdevelopmental myostatin gene knockout
Welle, S., Bhatt, K., Pinkert, C. A., Tawil, R., & Thornton, C. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00531.2006 · Cited by 113
“This observation is consistent with studies of both constitutive myostatin knockout and postweaning inhibition of myostatin activity, in which excessive muscle growth was associated with increased protein/DNA ratios (6, 8, 14) or fiber hypertrophy without an increase in the number of myonuclei (1, 18).”
A myostatin and activin decoy receptor enhances bone formation in mice
Bialek, P., Parkington, J., Li, X., Gavin, D., Wallace, C., Zhang, J., Root, A., Yan, G., Warner, L., Seeherman, H. J., et al. (2014) · Bone · doi:10.1016/j.bone.2013.12.002 · Cited by 110
“The mouse Mstn monoclonal antibodies (clone JA16) were generated and purified as previously described [40].”
MethodCancer cachexia: multilevel metabolic dysfunction
Díaz, M. B., Rohm, M., & Herzig, S. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01167-9 · Cited by 122
“Blocking myostatin, a member of the TGF-β superfamily and negative regulator of muscle growth 234 , using LY2495655, an anti-myostatin antibody, plus standard-of-care chemotherapy in a randomized phase 2 trial failed to provide clinical benefits in patients with pancreatic cancer and cachexia,…”
Myostatin in the Pathophysiology of Skeletal Muscle
Bonnieu, A., Carnac, G., & Vernus, B. (2007) · Current Genomics · doi:10.2174/138920207783591672 · Cited by 121
“Accordingly, genetic inhibition of myostatin function or myostatin blockade by several agents (including myostatin antibodies, myostatin propeptide, follistatin-related proteins, soluble type II myostatin receptor) have been shown to be effective in increasing muscle mass and reducing disease severity in the mdx mouse…”
BackgroundMethodInfluentialRose, F. F., Mattis, V. B., Rindt, H., & Lorson, C. L. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddn426 · Cited by 106
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
Antibody-Directed Myostatin Inhibition Enhances Muscle Mass and Function in Tumor-Bearing Mice
Murphy, K. T., Chee, A., Gleeson, B. G., Naim, T., Swiderski, K., Koopman, R., & Lynch, G. S. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00121.2011 · Cited by 111
“Furthermore, inhibition of myostatin activity can enhance muscle mass in several disease models associated with muscle wasting, including the muscular dystrophies (7, 8, 35, 42), sarcopenia (33, 37), and disuse/limb casting (32).”
BackgroundCTGF/CCN‐2 over‐expression can directly induce features of skeletal muscle dystrophy
Morales, M. G., Cabello‐Verrugio, C., Santander, C., Cabrera, D., Goldschmeding, R., & Brandan, E. (2011) · The Journal of Pathology · doi:10.1002/path.2952 · Cited by 107
Townsend, D., Turner, I. I., Yasuda, S., Martindale, J. J., Davis, J., Shillingford, M. S., Kornegay, J. N., & Metzger, J. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41329 · Cited by 111
“Currently there are no effective therapies for the cardiomyopathy of DMD. Numerous therapeutic strategies have been proposed to impact striated muscle disease progression in DMD (6–12).”
Therapies for Musculoskeletal Disease: Can we Treat Two Birds with One Stone?
Girgis, C. M., Mokbel, N., & DiGirolamo, D. J. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0204-5 · Cited by 110
Characterization and identification of the inhibitory domain of GDF-8 propeptide
Jiang, M., Liang, L., Wang, S., Ratovitski, T., Holmstrom, J., Barker, C., & Stotish, R. L. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.085 · Cited by 119
“Administration of this antibody tomdxmice, a mouse model for Duchenne muscular dystrophy [26–28], results in the increase of skeletal muscle mass accompanied by an increase in muscle function [29].”
BackgroundMyostatin short interfering hairpin RNA gene transfer increases skeletal muscle mass
Magee, T. R., Artaza, J. N., Ferrini, M. G., Vernet, D., Zuniga, F. I., Cantini, L., Reisz‐Porszasz, S., Rajfer, J., & Gonzalez‐Cadavid, N. F. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.946 · Cited by 106
“against myostatin [16] or by crossing this mouse with”
BackgroundEvolving Therapeutic Strategies for Duchenne Muscular Dystrophy: Targeting Downstream Events
Tidball, J. G., & Wehling‐Henricks, M. (2004) · Pediatric Research · doi:10.1203/01.pdr.0000145578.01985.d0 · Cited by 121
“Strong support for this hope was provided independently by two investigative teams who showed that mdx mice that were null mutants for myostatin (125) and mdx mice that received intraperitoneal injections of anti-myostatin (126) showed increases in muscle mass and strength, with no reported, adverse side effects.”
BackgroundMethodRodino-Klapac, L. R., Janssen, P. M., Montgomery, C. L., Coley, B. D., Chicoine, L. G., Clark, K. R., & Mendell, J. R. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-45 · Cited by 104
“[7,8] Promising findings are also emerging from experimental gene replacement therapy in dystrophic mice [912] and dogs.”
Chopard, A., Hillock, S., & Jasmin, B. J. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00864.x · Cited by 117
“Thus, the use of myostatin as a target for counteracting skeletal muscle disuse atrophy remains to be further explored [184].”
BackgroundCell–matrix interactions in muscle disease
Carmignac, V., & Durbeej, M. (2011) · The Journal of Pathology · doi:10.1002/path.3020 · Cited by 113
St. Andre, M., Johnson, M., Bansal, P. N., Wellen, J., Robertson, A., Opsahl, A., Burch, P. M., Bialek, P., Morris, C., & Owens, J. (2017) · Skeletal Muscle · doi:10.1186/s13395-017-0141-y · Cited by 100
Murine models of atrophy, cachexia, and sarcopenia in skeletal muscle
Romanick, M., Thompson, L. V., & Brown-Borg, H. M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.03.011 · Cited by 92
“Some rodent models of neuromuscular disease have benefitted from the application of myostatin neutralizing antibodies with increased muscle fiber size (however not enhanced muscle function) [103,104].”
BackgroundMyostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis
Holzbaur, E. L. F., Howland, D. S., Weber, N., Wallace, K., She, Y., Kwak, S., Tchistiakova, L. A., Murphy, E., Hinson, J., Karim, R., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.05.009 · Cited by 101
Chandrasekharan, K., Yoon, J. H., Xu, Y., deVries, S., Camboni, M., Janssen, P. M. L., Varki, A., & Martin, P. T. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000692 · Cited by 104
Muscle wasting in cardiac cachexia
Strassburg, S., Springer, J., & Anker, S. D. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.03.013 · Cited by 116
Skeletal Muscle as a Paradigm for Regenerative Biology and Medicine
Gayraud-Morel, B., Chrétien, F., & Tajbakhsh, S. (2009) · Regenerative Medicine · doi:10.2217/17460751.4.2.293 · Cited by 95
Parsons, S. A., Millay, D. P., Sargent, M. A., McNally, E. M., & Molkentin, J. D. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051316 · Cited by 109
“Mice were administered a course of either MSTN antibody or control antibody once a week for a 3-month time period, as described previously.(9) At the end of the study, animals were sacrificed and the heart and gastrocnemius, plantaris, tibialis anterior, and quadriceps muscles were dissected out and weighed.”
MethodResultEmerging drugs for Duchenne muscular dystrophy
Malik, V., Rodino-Klapac, L. R., & Mendell, J. R. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.691965 · Cited by 97
“Thismyostatin neutralizing antibodywas shown to increasemuscle mass in immunodeficient mice by approximately 30% over 3 months, similar to the biological response demonstrated for other myostatin-neutralizing antibodies [64].”
BackgroundEffects of exosome-mediated delivery of myostatin propeptide on functional recovery of mdx mice
Ran, N., Gao, X., Dong, X., Li, J., Lin, C., Geng, M., & Yin, H. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119826 · Cited by 98
Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice
Cm, L., Yang, Z., Liu, C.-W., Wang, R., Tien, P., Dale, R., & Sun, L.-Q. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303016 · Cited by 114
van den Bergen, J. C., Hiller, M., Böhringer, S., Vijfhuizen, L., Ginjaar, H. B., Chaouch, A., Bushby, K. M. D., Straub, V. W., Scoto, M., Çırak, S., et al. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308409 · Cited by 107
Advances in livestock genomics: Opening the barn door
Womack, J. E. (2005) · Genome Research · doi:10.1101/gr.3809105 · Cited by 119
Viral-mediated gene therapy for the muscular dystrophies: Successes, limitations and recent advances
Odom, G. L., Gregorevic, P., & Chamberlain, J. S. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.09.007 · Cited by 115
“Whatever the mechanism, it likely does not involve compensation by utrophin [256].”
BackgroundMyostatin and muscle atrophy during chronic kidney disease
Bataille, S., Chauveau, P., Fouque, D. P., Aparicio, M., & Koppe, L. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa129 · Cited by 103
The Physiology of Sports Injuries and Repair Processes
Kelc, R., Naranđa, J., Kuhta, M., & Vogrin, M. (2013) · InTech eBooks · doi:10.5772/54234 · Cited by 118
“Blocking of the MSTN signaling transduction pathway by specific inhibitors and genetic manipulations has been shown to result in a dramatic in‐ crease of skeletal muscle mass [70].”
BackgroundIDENTIFICATION OF A ZEBRAFISH MODEL OF MUSCULAR DYSTROPHY
Bassett, D. I., & Currie, P. D. (2004) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2004.04030.x · Cited by 104
Serum Myostatin is Upregulated in Obesity and Correlates with Insulin Resistance in Humans
Amor, M., Itariu, B. K., Moreno-Viedma, V., Keindl, M., Jürets, A., Prager, G., Langer, F., Grablowitz, V., Zeyda, M., & Stulnig, T. M. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0641-5546 · Cited by 93
Qiao, C., Li, J., Zheng, H., Bogan, J., Li, J., Yuan, Z., Zhang, C., Bogan, D., Kornegay, J., & Xiao, X. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.135 · Cited by 89
“Administration of a myostatin-blocking antibody increased muscle strength and decreased muscle degeneration in mdx mice (Bogdanovich et al., 2002).”
BackgroundImprovements in Gene Editing Technology Boost Its Applications in Livestock
Périssé, I. V., Fan, Z., Singina, G. N., White, K. L., & Polejaeva, I. A. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.614688 · Cited by 96
Functional Substitution by TAT-Utrophin in Dystrophin-Deficient Mice
Sonnemann, K. J., Heun‐Johnson, H., Turner, A., Baltgalvis, K. A., Lowe, D. A., & Ervasti, J. M. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000083 · Cited by 106
“effects of dystrophin deficiency in animal models [2–9], there are”
BackgroundMartin, P. T., Xu, R., Rodino-Klapac, L. R., Oglesbay, E., Camboni, M., Montgomery, C. L., Shontz, K., Chicoine, L. G., Clark, K. R., Sahenk, Z., et al. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00456.2008 · Cited by 92
“Likewise, treatment of mdx muscles with heregulin(24), myostatin inhibitors(3, 4), creatine(28), calcium channel”
BackgroundMarceca, G. P., Londhe, P., & Calore, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00298 · Cited by 93
“Mstn (also known as GDF8) is primary synthesized by SM cells and functions as an autocrine factor causing a strong downregulation ofmyogenesis (78, 79), while inhibition of its expression/function leads to a dramatic increase in muscle mass (80, 81).”
BackgroundMyostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders?
Suh, J., & Lee, Y. (2020) · Journal of Bone Metabolism · doi:10.11005/jbm.2020.27.3.151 · Cited by 104
“Despite encouraging results of the preclinical studies [59] and safety profile, Myo-29 failed to show significant improvements in muscle strength or function likely due to high rate of clearance,[60] which halted its further development.”
ResultAdaptive processes in skeletal muscle: molecular regulators and genetic influences.
Stewart, C. E., & Rittweger, J. (2006) · PubMed · Cited by 120
Definition of the unique human extraocular muscle allotype by expression profiling
Fischer, M. D., Budak, M. T., Bakay, M. A., Gorospe, J. R. M., Kjellgren, D., Domellöf, F. P., Hoffman, E. P., & Khurana, T. S. (2005) · Physiological Genomics · doi:10.1152/physiolgenomics.00158.2004 · Cited by 91
“Indeed, increasing myogenesis/regeneration using pharmacological myostatin blockade has been shown to ameliorate the dystrophic phenotype in the mouse model of muscular dystrophy (6).”
BackgroundMethodSelf-citationMyostatin auto-regulates its expression by feedback loop through Smad7 dependent mechanism.
Forbes, D., Jackman, M., Bishop, A., Thomas, M., Kambadur, R., & Sharma, M. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20477 · Cited by 90
“Subsequent to the phosphorylation of type I receptor, myostatin has been shown to activate R-smads, Smad2 and Smad3 to transduce signalling (Bogdanovich et al., 2002; Langley et al., 2002; Rebbapragada et al., 2003).”
BackgroundMyostatin does not regulate cardiac hypertrophy or fibrosis
Cohn, R. D., Liang, H.-Y., Shetty, R., Abraham, T. P., & Wagner, K. R. (2007) · Neuromuscular Disorders · doi:10.1016/j.nmd.2007.01.011 · Cited by 99
“myostatin ameliorates the dystrophic phenotype in mdx mice (8,9).”
BackgroundThe role of satellite cells in muscle hypertrophy
Blaauw, B., & Reggiani, C. (2014) · Journal of Muscle Research and Cell Motility · doi:10.1007/s10974-014-9376-y · Cited by 97
“This increased number of fibers is very likely an event which occurs during early stages of development, since treatment of adult mice with antibodies for myostatin does not affect fiber number, but only increases fiber size (Bogdanovich et al. 2002).”
Role of myostatin in metabolism
Gonzalez-Cadavid, N. F., & Bhasin, S. (2004) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000134365.99523.7f · Cited by 88
Extracellular Regulation of Myostatin: A Molecular Rheostat for Muscle Mass
Lee, S.-J. (2010) · Immunology‚ Endocrine & Metabolic Agents in Medicinal Chemistry · doi:10.2174/187152210793663748 · Cited by 87
“Moreover, pharmacological agents capable of blocking MSTN activity have been shown to cause significant increases in muscle growth when administered systemically to adult mice [9-12], demonstrating that MSTN plays a critical role in regulating muscle homeostasis postnatally by suppressing muscle growth.”
BackgroundShimizu‐Motohashi, Y., Miyatake, S., Komaki, H., Takeda, S., & Aoki, Y. (2016) · Europe PMC (PubMed Central) · Cited by 104
Cong, H., Sun, L., Liu, C., & Tien, P. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.057 · Cited by 77
“One of these, myostatin (growth differentiation factor [GDF]-8), is a major protein involved in regulating muscle growth and may be involved directly or indirectly in musclewasting conditions (Bogdanovich et al., 2002).”
Doran, P., Dowling, P., Lohan, J., McDonnell, K., Poetsch, S., & Ohlendieck, K. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04332.x · Cited by 102
Cabello‐Verrugio, C., Morales, M. G., Cabrera, D., Vio, C. P., & Brandan, E. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01354.x · Cited by 84
“After 5 days post-infection with adenovirus, mice were anaesthetized, tibialis anterior muscles was removed and the muscle contractile properties were measured as previously described [24, 25].”
MethodHan, D.-S., Chen, Y.-M., Lin, S.-Y., Chang, H.-H., Huang, T.-M., Chi, Y.-C., & Yang, W.-S. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04120.x · Cited by 83
Metadata
- Authors
- Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S.
- Affiliations
- University of Pennsylvania (US)
- Pfizer (United States) (US)
- Corresponding author
- Khurana, Tejvir S.
- Venue
- Nature
- Published
- 2002-11
- Volume
- 420
- Issue
- 6914
- Pages
- 418-421
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2083700023
- Semantic Scholar
- 590fb54cd1f2d89d44f4e1ad999be802dc756277
- Cited by
- 831
- References
- 31
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 19 · 2023: 15 · 2022: 21 · 2021: 20 · 2020: 23 · 2019: 32 · 2018: 23 · 2017: 34 · 2016: 28 · 2015: 43 · 2014: 34 · 2013: 38 · 2012: 48
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Keywords
- myostatin, Duchenne muscular dystrophy, mdx mice, muscle atrophy, blocking antibodies, muscle mass, muscle strength, muscle degeneration, creatine kinase, TGF-beta superfamily, skeletal muscle growth
- MeSH terms
- Animals, Antibodies, Body Weight, Creatine Kinase, Male, Muscular Dystrophy, Animal, Organ Size, Transforming Growth Factor beta, Mice, Inbred mdx, Muscle, Skeletal, Muscle Fibers, Skeletal, Muscular Dystrophy, Duchenne, Mice, Myostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.